Eintrag weiter verarbeiten
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production
Gespeichert in:
| Zeitschriftentitel: | Arthritis & Rheumatism |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , , |
| In: | Arthritis & Rheumatism, 64, 2012, 11, S. 3531-3542 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
LaBranche, Timothy P. Jesson, Michael I. Radi, Zaher A. Storer, Chad E. Guzova, Julia A. Bonar, Sheri L. Thompson, Janice M. Happa, Fernando A. Stewart, Zachary S. Zhan, Yutian Bollinger, Chris S. Bansal, Prashant N. Wellen, Jeremy W. Wilkie, Dean P. Bailey, Steven A. Symanowicz, Peter T. Hegen, Martin Head, Richard D. Kishore, Nandini Mbalaviele, Gabriel Meyer, Debra M. LaBranche, Timothy P. Jesson, Michael I. Radi, Zaher A. Storer, Chad E. Guzova, Julia A. Bonar, Sheri L. Thompson, Janice M. Happa, Fernando A. Stewart, Zachary S. Zhan, Yutian Bollinger, Chris S. Bansal, Prashant N. Wellen, Jeremy W. Wilkie, Dean P. Bailey, Steven A. Symanowicz, Peter T. Hegen, Martin Head, Richard D. Kishore, Nandini Mbalaviele, Gabriel Meyer, Debra M. |
|---|---|
| author |
LaBranche, Timothy P. Jesson, Michael I. Radi, Zaher A. Storer, Chad E. Guzova, Julia A. Bonar, Sheri L. Thompson, Janice M. Happa, Fernando A. Stewart, Zachary S. Zhan, Yutian Bollinger, Chris S. Bansal, Prashant N. Wellen, Jeremy W. Wilkie, Dean P. Bailey, Steven A. Symanowicz, Peter T. Hegen, Martin Head, Richard D. Kishore, Nandini Mbalaviele, Gabriel Meyer, Debra M. |
| spellingShingle |
LaBranche, Timothy P. Jesson, Michael I. Radi, Zaher A. Storer, Chad E. Guzova, Julia A. Bonar, Sheri L. Thompson, Janice M. Happa, Fernando A. Stewart, Zachary S. Zhan, Yutian Bollinger, Chris S. Bansal, Prashant N. Wellen, Jeremy W. Wilkie, Dean P. Bailey, Steven A. Symanowicz, Peter T. Hegen, Martin Head, Richard D. Kishore, Nandini Mbalaviele, Gabriel Meyer, Debra M. Arthritis & Rheumatism JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production Pharmacology (medical) Immunology Rheumatology Immunology and Allergy |
| author_sort |
labranche, timothy p. |
| spelling |
LaBranche, Timothy P. Jesson, Michael I. Radi, Zaher A. Storer, Chad E. Guzova, Julia A. Bonar, Sheri L. Thompson, Janice M. Happa, Fernando A. Stewart, Zachary S. Zhan, Yutian Bollinger, Chris S. Bansal, Prashant N. Wellen, Jeremy W. Wilkie, Dean P. Bailey, Steven A. Symanowicz, Peter T. Hegen, Martin Head, Richard D. Kishore, Nandini Mbalaviele, Gabriel Meyer, Debra M. 0004-3591 1529-0131 Wiley Pharmacology (medical) Immunology Rheumatology Immunology and Allergy http://dx.doi.org/10.1002/art.34649 <jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>The mechanistic link between Janus kinase (JAK) signaling and structural damage to arthritic joints in rheumatoid arthritis (RA) is poorly understood. This study was undertaken to investigate how selective inhibition of JAK with tofacitinib (CP‐690,550) affects osteoclast‐mediated bone resorption in a rat adjuvant‐induced arthritis (AIA) model, as well as human T lymphocyte RANKL production and human osteoclast differentiation and function.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Hind paw edema, inflammatory cell infiltration, and osteoclast‐mediated bone resorption in rat AIA were assessed using plethysmography, histopathologic analysis, and immunohistochemistry; plasma and hind paw tissue levels of cytokines and chemokines (including RANKL) were also assessed. In vitro RANKL production by activated human T lymphocytes was evaluated by immunoassay, while human osteoclast differentiation and function were assessed via quantitative tartrate‐resistant acid phosphatase staining and degradation of human bone collagen, respectively.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Edema, inflammation, and osteoclast‐mediated bone resorption in rats with AIA were dramatically reduced after 7 days of treatment with the JAK inhibitor, which correlated with reduced numbers of CD68/ED‐1+, CD3+, and RANKL+ cells in the paws; interleukin‐6 (transcript and protein) levels were rapidly reduced in paw tissue within 4 hours of the first dose, whereas it took 4–7 days of therapy for RANKL levels to decrease. Tofacitinib did not impact human osteoclast differentiation or function, but did decrease human T lymphocyte RANKL production in a concentration‐dependent manner.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>These results suggest that the JAK inhibitor tofacitinib suppresses osteoclast‐mediated structural damage to arthritic joints, and this effect is secondary to decreased RANKL production.</jats:p></jats:sec> JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production Arthritis & Rheumatism |
| doi_str_mv |
10.1002/art.34649 |
| facet_avail |
Online Free |
| finc_class_facet |
Chemie und Pharmazie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuMzQ2NDk |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuMzQ2NDk |
| institution |
DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 |
| imprint |
Wiley, 2012 |
| imprint_str_mv |
Wiley, 2012 |
| issn |
0004-3591 1529-0131 |
| issn_str_mv |
0004-3591 1529-0131 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
labranche2012jakinhibitionwithtofacitinibsuppressesarthriticjointstructuraldamagethroughdecreasedranklproduction |
| publishDateSort |
2012 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Arthritis & Rheumatism |
| source_id |
49 |
| title |
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| title_unstemmed |
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| title_full |
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| title_fullStr |
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| title_full_unstemmed |
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| title_short |
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| title_sort |
jak inhibition with tofacitinib suppresses arthritic joint structural damage through decreased rankl production |
| topic |
Pharmacology (medical) Immunology Rheumatology Immunology and Allergy |
| url |
http://dx.doi.org/10.1002/art.34649 |
| publishDate |
2012 |
| physical |
3531-3542 |
| description |
<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>The mechanistic link between Janus kinase (JAK) signaling and structural damage to arthritic joints in rheumatoid arthritis (RA) is poorly understood. This study was undertaken to investigate how selective inhibition of JAK with tofacitinib (CP‐690,550) affects osteoclast‐mediated bone resorption in a rat adjuvant‐induced arthritis (AIA) model, as well as human T lymphocyte RANKL production and human osteoclast differentiation and function.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Hind paw edema, inflammatory cell infiltration, and osteoclast‐mediated bone resorption in rat AIA were assessed using plethysmography, histopathologic analysis, and immunohistochemistry; plasma and hind paw tissue levels of cytokines and chemokines (including RANKL) were also assessed. In vitro RANKL production by activated human T lymphocytes was evaluated by immunoassay, while human osteoclast differentiation and function were assessed via quantitative tartrate‐resistant acid phosphatase staining and degradation of human bone collagen, respectively.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Edema, inflammation, and osteoclast‐mediated bone resorption in rats with AIA were dramatically reduced after 7 days of treatment with the JAK inhibitor, which correlated with reduced numbers of CD68/ED‐1+, CD3+, and RANKL+ cells in the paws; interleukin‐6 (transcript and protein) levels were rapidly reduced in paw tissue within 4 hours of the first dose, whereas it took 4–7 days of therapy for RANKL levels to decrease. Tofacitinib did not impact human osteoclast differentiation or function, but did decrease human T lymphocyte RANKL production in a concentration‐dependent manner.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>These results suggest that the JAK inhibitor tofacitinib suppresses osteoclast‐mediated structural damage to arthritic joints, and this effect is secondary to decreased RANKL production.</jats:p></jats:sec> |
| container_issue |
11 |
| container_start_page |
3531 |
| container_title |
Arthritis & Rheumatism |
| container_volume |
64 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343356587638789 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:50:25.17Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=JAK+inhibition+with+tofacitinib+suppresses+arthritic+joint+structural+damage+through+decreased+RANKL+production&rft.date=2012-11-01&genre=article&issn=1529-0131&volume=64&issue=11&spage=3531&epage=3542&pages=3531-3542&jtitle=Arthritis+%26+Rheumatism&atitle=JAK+inhibition+with+tofacitinib+suppresses+arthritic+joint+structural+damage+through+decreased+RANKL+production&aulast=Meyer&aufirst=Debra+M.&rft_id=info%3Adoi%2F10.1002%2Fart.34649&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343356587638789 |
| author | LaBranche, Timothy P., Jesson, Michael I., Radi, Zaher A., Storer, Chad E., Guzova, Julia A., Bonar, Sheri L., Thompson, Janice M., Happa, Fernando A., Stewart, Zachary S., Zhan, Yutian, Bollinger, Chris S., Bansal, Prashant N., Wellen, Jeremy W., Wilkie, Dean P., Bailey, Steven A., Symanowicz, Peter T., Hegen, Martin, Head, Richard D., Kishore, Nandini, Mbalaviele, Gabriel, Meyer, Debra M. |
| author_facet | LaBranche, Timothy P., Jesson, Michael I., Radi, Zaher A., Storer, Chad E., Guzova, Julia A., Bonar, Sheri L., Thompson, Janice M., Happa, Fernando A., Stewart, Zachary S., Zhan, Yutian, Bollinger, Chris S., Bansal, Prashant N., Wellen, Jeremy W., Wilkie, Dean P., Bailey, Steven A., Symanowicz, Peter T., Hegen, Martin, Head, Richard D., Kishore, Nandini, Mbalaviele, Gabriel, Meyer, Debra M., LaBranche, Timothy P., Jesson, Michael I., Radi, Zaher A., Storer, Chad E., Guzova, Julia A., Bonar, Sheri L., Thompson, Janice M., Happa, Fernando A., Stewart, Zachary S., Zhan, Yutian, Bollinger, Chris S., Bansal, Prashant N., Wellen, Jeremy W., Wilkie, Dean P., Bailey, Steven A., Symanowicz, Peter T., Hegen, Martin, Head, Richard D., Kishore, Nandini, Mbalaviele, Gabriel, Meyer, Debra M. |
| author_sort | labranche, timothy p. |
| container_issue | 11 |
| container_start_page | 3531 |
| container_title | Arthritis & Rheumatism |
| container_volume | 64 |
| description | <jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>The mechanistic link between Janus kinase (JAK) signaling and structural damage to arthritic joints in rheumatoid arthritis (RA) is poorly understood. This study was undertaken to investigate how selective inhibition of JAK with tofacitinib (CP‐690,550) affects osteoclast‐mediated bone resorption in a rat adjuvant‐induced arthritis (AIA) model, as well as human T lymphocyte RANKL production and human osteoclast differentiation and function.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Hind paw edema, inflammatory cell infiltration, and osteoclast‐mediated bone resorption in rat AIA were assessed using plethysmography, histopathologic analysis, and immunohistochemistry; plasma and hind paw tissue levels of cytokines and chemokines (including RANKL) were also assessed. In vitro RANKL production by activated human T lymphocytes was evaluated by immunoassay, while human osteoclast differentiation and function were assessed via quantitative tartrate‐resistant acid phosphatase staining and degradation of human bone collagen, respectively.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Edema, inflammation, and osteoclast‐mediated bone resorption in rats with AIA were dramatically reduced after 7 days of treatment with the JAK inhibitor, which correlated with reduced numbers of CD68/ED‐1+, CD3+, and RANKL+ cells in the paws; interleukin‐6 (transcript and protein) levels were rapidly reduced in paw tissue within 4 hours of the first dose, whereas it took 4–7 days of therapy for RANKL levels to decrease. Tofacitinib did not impact human osteoclast differentiation or function, but did decrease human T lymphocyte RANKL production in a concentration‐dependent manner.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>These results suggest that the JAK inhibitor tofacitinib suppresses osteoclast‐mediated structural damage to arthritic joints, and this effect is secondary to decreased RANKL production.</jats:p></jats:sec> |
| doi_str_mv | 10.1002/art.34649 |
| facet_avail | Online, Free |
| finc_class_facet | Chemie und Pharmazie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuMzQ2NDk |
| imprint | Wiley, 2012 |
| imprint_str_mv | Wiley, 2012 |
| institution | DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1 |
| issn | 0004-3591, 1529-0131 |
| issn_str_mv | 0004-3591, 1529-0131 |
| language | English |
| last_indexed | 2024-03-01T16:50:25.17Z |
| match_str | labranche2012jakinhibitionwithtofacitinibsuppressesarthriticjointstructuraldamagethroughdecreasedranklproduction |
| mega_collection | Wiley (CrossRef) |
| physical | 3531-3542 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Arthritis & Rheumatism |
| source_id | 49 |
| spelling | LaBranche, Timothy P. Jesson, Michael I. Radi, Zaher A. Storer, Chad E. Guzova, Julia A. Bonar, Sheri L. Thompson, Janice M. Happa, Fernando A. Stewart, Zachary S. Zhan, Yutian Bollinger, Chris S. Bansal, Prashant N. Wellen, Jeremy W. Wilkie, Dean P. Bailey, Steven A. Symanowicz, Peter T. Hegen, Martin Head, Richard D. Kishore, Nandini Mbalaviele, Gabriel Meyer, Debra M. 0004-3591 1529-0131 Wiley Pharmacology (medical) Immunology Rheumatology Immunology and Allergy http://dx.doi.org/10.1002/art.34649 <jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>The mechanistic link between Janus kinase (JAK) signaling and structural damage to arthritic joints in rheumatoid arthritis (RA) is poorly understood. This study was undertaken to investigate how selective inhibition of JAK with tofacitinib (CP‐690,550) affects osteoclast‐mediated bone resorption in a rat adjuvant‐induced arthritis (AIA) model, as well as human T lymphocyte RANKL production and human osteoclast differentiation and function.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Hind paw edema, inflammatory cell infiltration, and osteoclast‐mediated bone resorption in rat AIA were assessed using plethysmography, histopathologic analysis, and immunohistochemistry; plasma and hind paw tissue levels of cytokines and chemokines (including RANKL) were also assessed. In vitro RANKL production by activated human T lymphocytes was evaluated by immunoassay, while human osteoclast differentiation and function were assessed via quantitative tartrate‐resistant acid phosphatase staining and degradation of human bone collagen, respectively.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Edema, inflammation, and osteoclast‐mediated bone resorption in rats with AIA were dramatically reduced after 7 days of treatment with the JAK inhibitor, which correlated with reduced numbers of CD68/ED‐1+, CD3+, and RANKL+ cells in the paws; interleukin‐6 (transcript and protein) levels were rapidly reduced in paw tissue within 4 hours of the first dose, whereas it took 4–7 days of therapy for RANKL levels to decrease. Tofacitinib did not impact human osteoclast differentiation or function, but did decrease human T lymphocyte RANKL production in a concentration‐dependent manner.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>These results suggest that the JAK inhibitor tofacitinib suppresses osteoclast‐mediated structural damage to arthritic joints, and this effect is secondary to decreased RANKL production.</jats:p></jats:sec> JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production Arthritis & Rheumatism |
| spellingShingle | LaBranche, Timothy P., Jesson, Michael I., Radi, Zaher A., Storer, Chad E., Guzova, Julia A., Bonar, Sheri L., Thompson, Janice M., Happa, Fernando A., Stewart, Zachary S., Zhan, Yutian, Bollinger, Chris S., Bansal, Prashant N., Wellen, Jeremy W., Wilkie, Dean P., Bailey, Steven A., Symanowicz, Peter T., Hegen, Martin, Head, Richard D., Kishore, Nandini, Mbalaviele, Gabriel, Meyer, Debra M., Arthritis & Rheumatism, JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production, Pharmacology (medical), Immunology, Rheumatology, Immunology and Allergy |
| title | JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| title_full | JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| title_fullStr | JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| title_full_unstemmed | JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| title_short | JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| title_sort | jak inhibition with tofacitinib suppresses arthritic joint structural damage through decreased rankl production |
| title_unstemmed | JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production |
| topic | Pharmacology (medical), Immunology, Rheumatology, Immunology and Allergy |
| url | http://dx.doi.org/10.1002/art.34649 |